Calprotectin Citations Archives - Page 3 of 4 - Buhlmann Diagnostics Corp

Category: Calprotectin Citations

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.

Highlight from this Publication:

“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
Continue Reading

Fecal Calprotectin in Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood. Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi: 10.2147/CEG.S51902

Highlight from this Publication

“The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features of an individual patient.”
Continue Reading

Diagnostic Accuracy and Clinical Application of Faecal Calprotectin in Adult Patients Presenting with Gastrointestinal Symptoms in Primary Care

BÜHLMANN fCAL®ELISA Citation Pavlidis, P ,Pavlidis P, Chedgy FJ, Tibble JA. Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care, Scandinavian Journal of Gastroenterology. 2013 Sep;48(9):1048-54. doi: 10.3109/00365521.2013.816771.

Highlight from this Publication 

“This study provides the first evidence on the use of fCal [BÜHLMANN fCAL® ELISA]testing in primary care…..to be used as part of the pathway for management of patients with suspected IBS.”
Continue Reading

Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy

Quantum Blue® fCAL Citation: Ferreiro-Iglesias, R. Barreiro-de Acosta M, Otero Santiago M, Lorenzo Gonzalez A, Alonso de la Peña C, Benitez Estevez AJ, Dominguez-Muñoz JE., Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance IFX Therapy. J Clin Gastroenterol. 2016 Feb;50(2):147-51. doi: 10.1097/MCG.0000000000000312. Highlight from this Publication “We found FC to
Continue Reading

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

BÜHLMANN fCAL® ELISA Citation Theede, K. ,Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis, Inflamm Bowel Dis. 2016 May;22(5):1042-8. doi: 10.1097/MIB.0000000000000736. Highlights from this Publication “…our histological inflammatory activity score is closely related to the concentration of FC and thereby has the advantage
Continue Reading

Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients with Ulcerative Colitis In Clinical And Endoscopic Remission

BÜHLMANN fCAL® ELISA Citation Guardiola, J, Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P.  Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients with Ulcerative Colitis In Clinical And Endoscopic Remission, Clinical Gastroenterology and Hepatology.  2014 Nov;12(11):1865-70. doi: 10.1016/j.cgh.2014.06.020. “…an FC value less than 155 mg/g is a reliable indicator of the
Continue Reading

Comparison of the Liaison® Calprotectin Kit with a Well-Established Point of Care Test (Quantum Blue — Bühlmann-Alere®) in Terms of Analytical Performances and Ability to Detect Relapses Amongst a Crohn Population in Follow-up

Quantum Blue®  fCAL Citation: Delefortrie, Q. Schatt P, Grimmelprez A, Gohy P, Deltour D, Collard G, Vankerkhoven P. Comparison of the Liaison® Calprotectin kit with a well-established point of care test (Quantum Blue — Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up, Clinical Biochemistry. 2016 Feb;49(3):268-73. doi: 10.1016/j.clinbiochem.2015.10.010
Continue Reading

Comparison of Fecal Inflammatory Markers in Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Wright, E. K., et al., 2016, Comparison of Fecal Inflammatory Markers in Crohn’s Disease, Inflamm Bowel Dis. 2016 May;22(5):1086-94. doi: 10.1097/MIB.0000000000000671. “This study shows that FC is the optimal marker for diagnosing and monitoring endoscopic postoperative Recurrence”. Learn More
Continue Reading

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery

BÜHLMANN fCAL® ELISA Citation Wright, E. K., , Kamm MA, De Cruz P, Hamilton AL et. al. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery, Gastroenterology 2015 May;148(5):938-947.e1. doi: 10.1053/j.gastro.2015.01.026. Highlights from this Publication “The present study has shown that FC concentration is sufficiently sensitive to monitor for recurrence of
Continue Reading

Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study,

Quantum Blue® fCAL Citation: Voiosu T Benguş A, Dinu R, Voiosu AM, Bălănescu P, Băicuş C, Diculescu M, Voiosu R, Mateescu B.  Rapid Fecal Calprotectin Level Assessment and the SIBDQ Score Can Accurately Detect Active Mucosal Inflammation in IBD Patients in Clinical Remission: a Prospective Study, J Gastrointestin Liver Dis.  2014 Sep;23(3):273-8. doi: 10.15403/jgld.2014.1121.233.thv. Highlight from
Continue Reading